Abbott (NYSE: ABT) today the FDA approved its CardioMEMS Hero next-generation pulmonary artery (PA) pressure reader.
Delve into the field of pulmonary hypertension as GSK places a $950M bet on 35Pharma's candidate HS235 following the footsteps of Winrevair.
The Food and Drug Administration awarded approval to CardioMEMS Hero, a new version of the device that patients use to take daily pulmonary artery pressure readings. Abbott has made Hero smaller and ...
Inhaled seralutinib demonstrated clinical activity in high-risk pulmonary arterial hypertension patients despite missing its primary phase 3 endpoint.
According to a Center for Healthcare Quality and Payment Reform report, 756 hospitals in the rural United States are at risk ...
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a ...
Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...
Panelists discuss how pulmonary arterial hypertension diagnosis requires comprehensive evaluation including right heart catheterization to confirm hemodynamic criteria, with normal mean PA pressure ...
Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...
Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best penny stocks under $1 to buy right now. On February 23, Gossamer Bio ...
A pulmonary embolism was the immediate cause of death for actor and comedian Catherine O’Hara. It’s a serious condition in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results